Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative ... Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

Further evaluation of the antitumor activity of the triple variant in B-lymphoma cells and rituximab ... treatment for human B-cell lymphoproliferative disorders. “In conclusion, the rituximab ...

Lymphoproliferative disorders can be pretty serious, as they mean your immune system doesn't work the way it should. They can ...

EBV latency has been classified into three types: type I (Burkitt's lymphoma), in which only ... and type III (lymphoproliferative diseases in immunosuppressed individuals), in which five EBNAs ...

My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin ...

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a ...

CMC-544 has high efficacy in combination with rituximab for follicular lymphoma (FL) and diffuse large B-cell lymphoma, at the expense of moderate toxicity. BL22 and HA22 have high durable ...